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Sunset of Code Allowing Practitioner-
Signed Immunization Protocols
As a reminder, the law that authorizes pharmacists 
to administer vaccinations under a practitioner-signed 
protocol will sunset, or expire, on June 30, 2021. The 
law had been set to sunset on June 30, 2020, but was 
extended for one year during the 2020 legislative session. 
Beginning July 1, 2021, pharmacists are authorized to 
order and administer vaccinations under the Iowa Board 
of Pharmacy’s statewide protocol or pursuant to a patient-
specific prescription issued by a practitioner.
Reminder to Pharmacists Whose 
Licenses Expired in 2020
For pharmacists whose licenses expired June 30, 2020, 
the 2020 Iowa Legislature provided a one-year extension for 
renewal and completion of required continuing education 
(CE). Pharmacists whose licenses expired June 30, 2020, 
and have not yet renewed or completed the required CE 
are reminded that renewals must be completed by June 
30, 2021, in addition to all CE. Also note that the one-year 
extension does not further extend the expiration of the 
license upon renewal. A pharmacist whose license expired 
June 30, 2020, and renews prior to June 30, 2021, will need 
to renew again no later than June 30, 2022. The one-year 
extension of the completion of CE also does not extend the 
subsequent requirement to complete 30 hours of CE prior 
to the pharmacist’s 2022 renewal.
89th General Assembly – 2021 Session
The 89th General Assembly gaveled into session on 
January 11, 2021, for the first session of its term. The Board 
has submitted two bills it seeks to have considered for 
changes to the Iowa Code. The Board’s pharmacy practice 
bill seeks to:
 ♦ remove the one-year limit of a technician trainee 
registration;
 ♦ generalize the language relating to delegation of 
pharmacy functions to technicians and support 
persons; 
 ♦ require an outsourcing facility to submit evidence of 
an inspection conducted within the two years prior to 
its application for licensure or renewal; or
 ♦ emphatically permit the Board to share certain 
information with Food and Drug Administration 
(FDA) which may be facilitated by the National 
Association of Boards of Pharmacy® (NABP®) 
Information Sharing Network, to comply with FDA 
memorandum of understanding.
The Board’s controlled substances (CS) bill seeks 
to permanently schedule substances that have been 
temporarily scheduled since the last session and make 
conforming changes to match the federal Controlled 
Substances Act (CSA). 
Licensees and registrants are encouraged to reach out to 
their legislators to provide input and comments about the 
Board’s bills. Information about legislators can be found 
by visiting www.legis.iowa.gov/legislators
Recent Rulemaking
The Board has recently adopted changes to rules that 
became effective on February 2, 2021. The changes clarify 
that the information needed for a pharmacist to conduct a 
complete drug utilization review must be collected, and 
that the pharmacist can delegate collection of the required 
information to a technician or intern. The rules also now 
require that a prescription submitted electronically must 
include a phone number at which the prescriber can be 
contacted to resolve prescription-related issues. The CS 
rules were amended to clarify that a registrant’s perpetual 
inventory log must always accurately reflect the actual 
on-hand inventory of those substances. Licensees and 
registrants are encouraged to review the Board’s rules at 
pharmacy.iowa.gov/ruleslaws and reach out to their local 
compliance officer with any questions.
Unfortunately, some practice sites are still using syringes to 
administer IV vinCRIStine. Based on data collected in response 
to the ISMP Medication Safety Self Assessment for High Alert 
Medications between September 2017 and March 2018 from 442 
US hospitals, nearly 20% of respondents still used syringes at 
least part of the time, including 13% who always used syringes 
to administer IV vinCRIStine. Thus, the risk of accidental 
intrathecal injection still exists in the US and globally.
Dispensing vinCRIStine and other vinca alkaloids in a 
minibag of compatible solution, and not in a syringe, was among 
the very first ISMP Targeted Medication Safety Best Practices 
for Hospitals, which were launched in 20141. Then, in March 
2019, ISMP called on the FDA to eliminate all mention of syringe 
administration from official vinCRIStine labeling.2
ISMP has frequently referred to wrong route administration 
of vinCRIStine and vinca alkaloids as the “most serious of all 
medication errors.” Patients experience tremendous pain and are 
often aware of their impending death, which typically occurs 
within days or weeks. There is no effective reversal once the 
mistake is made. Even with the labeling change, there is nothing 
to stop health care practitioners from administering vinCRIStine 
via syringe (except if they can only get the drug dispensed in a 
minibag). We hope that every hospital and health system will 
investigate exactly how vinCRIStine is being administered at 
any site that uses the drug. It is time to end the practice of syringe 
administration by making it a requirement for all vinCRIStine 





What Pharmacists Need to Know About 
Biosimilar and Interchangeable Biological 
Products
This column was prepared by 
FDA, an agency within the US 
Department of Health and Hu-
man Services, that protects the 
public health by assuring the safety, effectiveness, and security 
of human and veterinary drugs, vaccines, and other biological 
products for human use, and medical devices. The agency also 
is responsible for the safety and security of our nation’s food 
supply, cosmetics, dietary supplements, products that give off 
electronic radiation, and for regulating tobacco products.
Biological products are a diverse category of products and 
are generally large, complex molecules. These products may 
be produced through biotechnology in a living system, such as 
a microorganism, plant cell, or animal cell, and are often more 
difficult to characterize than small molecule drugs. There are 
many types of biological products approved for use in the US, 
including therapeutic proteins (eg, filgrastim), monoclonal 
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DEA Publishes New Version of Pharmacist’s 
Manual
The latest version of the Pharmacist’s Manual: An 
Informational Outline of the Controlled Substances Act has 
been released by Drug Enforcement Administration’s (DEA’s) 
Diversion Control Division. The guide is provided to assist 
pharmacists in understanding the Federal Controlled Substances 
Act and its regulations as they pertain to the pharmacy 
profession. This edition has been updated to include information 
on the Secure and Responsible Drug Disposal Act of 2010, 
the Comprehensive Addiction and Recovery Act of 2016, and 
the SUPPORT for Patients and Communities Act of 2018, and 
replaces all versions of the guidance previously issued by the 
agency. The new Pharmacist’s Manual can be accessed by 
visiting the DEA website.
Time to End VinCRIStine Syringe 
Administration
This column was prepared 
by the Institute for Safe 
Medication Practices (ISMP), 
an ECRI affiliate. Have you 
experienced a medication 
error or close call? Report such incidents in confidence to 
ISMP’s National Medication Errors Reporting Program online at 
www.ismp.org or by email to ismpinfo@ismp.org to activate an 
alert system that reaches manufacturers, the medical community, 
and Food and Drug Administration (FDA). To read more about 
the risk reduction strategies that you can put into practice today, 
subscribe to the ISMP Medication Safety Alert!® newsletters at 
www.ismp.org.
At the request of FDA, Pfizer has revised the prescribing 
information and product packaging for vinCRIStine sulfate 
injection. Importantly, they have removed wording from the 
vinCRIStine package insert that described direct intravenous 
(IV) injection of vinCRIStine via a syringe. FDA recommended 
this revision at the request of ISMP, the National Comprehensive 
Cancer Network, and The Joint Commission.
The WARNINGS section of the package insert now states, “To 
reduce the potential for fatal medication errors due to incorrect 
route of administration, vinCRIStine sulfate injection should be 
diluted in a flexible plastic container and prominently labeled 
as indicated ‘FOR INTRAVENOUS USE ONLY—FATAL 
IF GIVEN BY OTHER ROUTES.’” More than 140 deaths 
are known to have occurred in the United States and globally 
due to accidental intrathecal injection of the drug via syringe, 
often when it was mixed up with, or wrongly assumed it was 
supposed to be given with, another drug meant for intrathecal 
administration, such as methotrexate. No such cases have 
been reported with dilution of vinCRIStine in a minibag, due 
to physical differences in the packaging and the need for an 
administration set.
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antibodies (eg, adalimumab), and vaccines (eg, influenza and 
tetanus). 
Section 351(k) of the Public Health Service Act (PHS Act) 
provides an abbreviated licensure pathway for biological 
products shown to be biosimilar to or interchangeable with an 
FDA-licensed reference product, which can help provide more 
affordable treatment options for patients. For example, on March 
23, 2020, FDA-approved insulin products were transitioned to 
regulation as biological products under the PHS Act, which 
means that transitioned insulin products are open to competition 
from future biosimilars, including interchangeable biosimilars. 
Key Terms for Biosimilar and Interchangeable 
Products
♦ Biosimilar Product: A biosimilar is a biological product
that is highly similar to and has no clinically meaningful
differences from an FDA-approved reference product.
♦ Interchangeable Product: An interchangeable product is
a biosimilar that meets additional approval requirements
and may be substituted for the reference product without
the intervention of the prescribing health care provider.
♦ Reference Product: A reference product is the single
biological product, already approved by FDA, against
which a proposed biosimilar or interchangeable product
is compared.
Are Biosimilars the Same as Generic Drugs?
Biosimilars and generic drugs are versions of brand name 
drugs and may offer more affordable treatment options to 
patients. Biosimilars and generics are approved through different 
abbreviated pathways that avoid duplicating costly clinical 
trials. But biosimilars are not generics, and there are important 
differences between them.
For example, the manufacturer of a generic drug must 
demonstrate, among other things, that the generic contains the 
same active ingredient as the brand name drug and that the 
generic is bioequivalent to the brand name drug. By contrast, 
biosimilar manufacturers must demonstrate that the biosimilar 
is highly similar to the reference product, except for minor 
differences in clinically inactive components, and that there 
are no clinically meaningful differences between the biosimilar 
and the reference product in terms of safety and effectiveness.
Unlike generics, biosimilars are generally prescribed by 
brand name by a health care provider, while interchangeables, 
like generics, may be substituted without the involvement of 
the prescribing health care provider, depending on state laws.
What is the Purple Book?
The Purple Book database contains information on FDA-
licensed (approved) biological products regulated by the Center 
for Drug Evaluation and Research, including licensed biosimilar 
and interchangeable products, and their reference products. It 
also contains information about all FDA-licensed allergenic, 
cellular, and gene therapy, hematologic, and vaccine products 
regulated by the Center for Biologics Evaluation and Research . 
The Purple Book has simple and advanced search capabilities 
and some information that you can find includes the proprietary 
(brand) name and nonproprietary (proper) name of biological 
products, applicant (company), dosage form, product presentation 
(eg, autoinjector, vial), route of administration, and strength. The 
Purple Book also will display FDA-approved interchangeable 
products and note with which brand product each interchangeable 
product may be substituted.
Are Therapeutic Equivalence Codes Assigned to 
Biological Products?
FDA does not assign therapeutic equivalence codes to 
biological products listed in the Purple Book like it does 
for small molecule drugs listed in the “Orange Book.” The 
Purple Book provides information about whether a biological 
product has been determined by FDA to be biosimilar to or 
interchangeable with a reference product.
Can Interchangeable Products Be Substituted at 
the Pharmacy?
Many states have laws that address pharmacy-level substi-
tution, including permitting substitution of interchangeable 
products, and the specific laws vary from state to state. 
There are currently no FDA-approved interchangeable 
products. Once there are, interchangeables, by definition, can 
be expected to produce the same clinical result as the reference 
product in any given patient.  
Biosimilar and interchangeable products meet FDA’s rigorous 
standards for approval, and patients and health care providers 
can be assured of the safety and effectiveness of these products, 
just as they would for the reference product. 






Final Insanitary Conditions at Compounding 
Facilities Guidance Released by FDA
Continuing efforts to protect patients from exposure to poor 
quality compounded drugs, FDA has published final guidance 
for compounding facilities regarding insanitary conditions. The 
final guidance, Insanitary Conditions at Compounding Facilities 
Guidance for Industry, provides recent examples of insanitary 
conditions that FDA has observed at compounding facilities 
and details corrective actions that facilities should take when 
they identify these conditions. The guidance is intended to help 
compounders identify and prevent such issues at their facilities.
While some compounders work hard to meet quality 
standards, FDA says its investigators continue to observe poor 
conditions that impact drug quality and that have the potential 
to harm patients. These include the presence of dirt, mold, 
insects, trash, peeling paint, unclean exhaust vents, and dirty 
high-efficiency particulate air filters.
In response to the draft guidance, FDA states that it has 
also added recommendations for compounders to use risk 
management tools to develop appropriate controls to prevent 
insanitary conditions at facilities. The guidance also addresses 
the regulatory actions that FDA may take in response to these 
conditions. 
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Narcan Dispensing Program Open to All 
Iowa Community Pharmacies
As the Board has previously reported, the Narcan 
Dispensing Program was initiated by a collaborative effort 
between the Iowa Department of Public Health, the Iowa 
Board of Pharmacy, and MedOne. This program provides 
electronic claims reimbursement to Iowa community 
pharmacies for dispensing Narcan® nasal spray to Iowa 
residents 18 years of age or older who may be at risk of 
an opioid-related overdose or to individuals who may be 
in a position to assist with an opioid-related overdose. 
Since the program’s rollout, 680 Narcan kits have been 
dispensed by 184 pharmacies to 673 patients. There are 
large areas of the state that are not yet represented by 
pharmacy participation! Here is information again on 
how to participate in this valuable program:
 ♦ Electronic claims may be submitted to MedOne and 
are reimbursable at the Iowa Department of Human 
Services’ actual acquisition cost list rate plus a $20 
dispensing fee. Funding for the program is limited 
and coordination of benefits is encouraged, but not 
required. 
 ♦ Pharmacies have multiple options for dispensing 
Narcan to an individual at risk of an opioid-related 
overdose. Authorization to dispense Narcan may 
be via a patient-specific prescription, the Board’s 
statewide protocol (with the dispensing pharmacist 
as the ordering practitioner), or Dr Caitlin Pedati’s 
statewide standing order.
More information can be found on the Board’s web page, 
from your local Board compliance officer, or by calling the 
Board office at 515/725-3492.
PMP Reporting of Single Dose or 
InstyMeds Medications at Discharge
The prescr ipt ion monitor ing program (PMP) 
administrators have recently received multiple questions 
regarding the dispensing of one or more single doses of a 
CS or the dispensing of a CS from an InstyMeds or similar 
machine, and whether those instances of dispensing are 
required to be reported to the PMP. Under Board Rule 
657—37.2(124), a “reportable prescription” includes “the 
dispensing of a controlled substance to an emergency 
department patient” and “the dispensing of a controlled 
substance or opioid antagonist to a patient upon discharge 
from a hospital or care facility.” As such, every CS or 
opioid antagonist which is dispensed to an emergency 
department patient or patient being discharged from the 
facility, for the medication to be self-administered by the 
Iowa Board of Pharmacy News March 2021
patient after discharge, must be reported to the PMP within 
one business day.
PMP Delegate Registrations – Reminder 
to Update
The PMP administrators would like to remind 
pharmacists who have pharmacy personnel registered 
with the PMP as a delegate to update the delegate’s status 
when the individual’s employment or registration status 
changes. For example, the delegate’s authorization should 
be removed when the individual is no longer serving as 
the pharmacist’s delegate (has terminated employment or 
moved to another location). If the delegate is a technician 
trainee, the delegate’s credentials should be updated when 
the technician attains national certification and becomes 
registered as a certified pharmacy technician.
Iowa Monitoring Program for Pharmacy 
Professionals
The Iowa Monitoring Program for Pharmacy Professionals 
(IMP3) was established in 2016 to monitor and support 
pharmacy professionals and student pharmacists who report 
difficulties with mental health, physical disabilities, and/
or drug and alcohol abuse or dependence. IMP3 believes 
the skills and reputation of pharmacy professionals and 
student pharmacists can be maintained if monitoring and 
supportive services are put in place at an early stage.
Self-reporting to IMP3 may include, but is not limited 
to, experiencing anger management concerns, mental 
health difficulties that are chronic or debilitating, alcohol 
and/or drug-related incidents or offenses, and diversion or 
misappropriation of a prescription drug or device for the 
individual’s personal use without proper authorization. 
IMP3 can assist pharmacy professionals and student 
pharmacists in obtaining necessary support, including 
healthy recovery from substance abuse, mental health 
difficulties, and/or physical disabilities.
Recognizing difficulties including, but not limited to, 
stress or anger management concerns, anxiety or depression 
symptoms, feeling out of control, burnout symptoms, etc, 
can be the first step to seeking support and recovery. IMP3 
is a confidential program that can provide an individualized 
agreement/contract, which will include safeguards designed 
to allow the professional to continue/return to practice with 
reasonable skill. It is IMP3’s hope that most participants in 
the program are actively practicing pharmacists.
If you or someone you know could benefit from IMP3, 
please contact Becky Carlson, IMP3 case manager, at 
IMP3@iowa.gov or 515/725-2253.
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Board Online Licensing System
The Board implemented a new licensing database in 
2018, and since that time has been developing online 
applications for all license and registration types. To date, 
all renewal applications have been converted to an online 
application for simple and efficient renewal. Board staff is 
actively working to develop an online option for all initial 
applications as well. So far, initial license or reactivation 
applications are available online for limited distributor 
licenses, third-party logistics provider licenses, pharmacist-
intern, pharmacist license by license transfer, technician 
trainee, and pharmacy support person. In the coming 
months, Board staff anticipates all remaining license and 
registration applications will be available for online use 
(CSA-business registrations, certified pharmacy technician, 
etc). Be sure to check the Board’s website at pharmacy.iowa 
.gov/online-services when looking for an initial license or 
registration application – it might be available online!
Licensee Reminders
Board licensing staff would like to provide the following 
reminders to license and registration applicants who are 
submitting paper applications.
Payment: When submitting applications for multiple 
locations, please remit a separate payment for each location. 
When one payment is submitted for multiple applications, 
all applications must be returned if there are any issues 
with one of the applications. However, if each application 
has its own separate payment, only the applications that 
have an error will be returned. Also, double check that the 
correct fee is being remitted, and make sure to include any 
late penalty or reinstatement fees that may be due. Do not 
send cash. 
Review: When submitting any application – particularly 
pharmacy support person and technician applications – 
review the entire application to ensure that it is complete 
and legible prior to submission.
Criminal history: Applicants with reportable criminal 
history are required to submit a written statement 
explaining the offense, a copy of the criminal complaint, 
and the judgment of conviction for each offense. Simply 
submitting a printout from Iowa Courts Online is not 
sufficient.
Upcoming Board Meetings – CE Available
Pharmacists and technicians are eligible to receive one 
hour of law CE when they attend a Board open session 
meeting. The Board holds approximately six meetings per 
year and conducts additional meetings via teleconference 
as warranted. The meetings include open session content 
as well as closed session content, which is not open to the 
public. Board meetings continue to be held virtually due 
to the coronavirus disease 2019 pandemic. The meeting 
agenda and information about how to attend is published 
approximately one week prior to each meeting and can be 
found on the Board’s website at pharmacy.iowa.gov. The 
Board has the following meetings tentatively scheduled:
 ♦ March 9-10, 2021
 ♦ May 11-12, 2021
 ♦ July 13-14, 2021
Get to Know Your Pharmacy Board 
Members – Ed McKenna
Ed McKenna, RPh, has dutifully served as a pharmacist 
member on the Board for nine years, including as vice 
chair. Ed’s third and final term will expire on April 30, 
2021. Governor Terry Branstad first appointed Ed to the 
Board in 2012, and he was subsequently reappointed to 
serve two additional three-year terms. Ed has provided his 
fellow Board members with his expertise in community and 
care facility pharmacy operations and services. During his 
terms, Ed has served on the Board’s Rules Committee and 
various task forces. He has also attended multiple NABP 
Annual Meetings. Ed continues to practice pharmacy at 
Hy-Vee Pharmacy in Storm Lake, IA. Ed wants people to 
understand that the Board does not just exist to discipline – 
that happens, of course – but the Board is also there to help. 
Ed’s favorite season is fall because baseball is winding 
down and football and hunting are starting. But he does 
not like what comes after that: winter! Ed has been a die-
hard Creighton superfan for decades and rarely – if ever – 
misses a basketball game. Ed also loves pheasant hunting 
and actually raises pheasants and quail to release into the 
wild to maintain the population. The Board and staff will 
sure miss Ed’s insight and entertainment!
